Edwards Lifesciences narrows full-year sales guidance as shares rise 6.5%

The medical device maker reported double-digit growth in its latest quarter, helped by expansion in its transcatheter aortic valve replacement division, and the stock climbed to $89.26 after hours.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.